Mucinous tubular and spindle cell carcinoma

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC

Mucinous tubular and spindle cell carcinoma
Mucinous tubular and spindle cell carcinoma
Synonyms	MTSCC
Pronounce	N/A
Specialty	N/A
Symptoms	Often asymptomatic, may present with hematuria, flank pain, or a palpable mass
Complications	Potential for metastasis
Onset	Typically in adults, more common in females
Duration	Chronic
Types
Causes	Unknown
Risks	Female gender, smoking, obesity
Diagnosis	Histopathology, imaging studies
Differential diagnosis	Renal cell carcinoma, papillary renal cell carcinoma
Prevention
Treatment	Surgical resection, nephrectomy
Medication
Prognosis	Generally favorable, low-grade malignancy
Frequency	Rare
Deaths	N/A

Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare type of renal cell carcinoma (RCC) that is characterized by its unique histological features. It is considered a low-grade malignancy with a generally favorable prognosis compared to other types of renal cell carcinomas.

Histopathology

MTSCC is distinguished by its histological appearance, which includes elongated tubules and spindle-shaped cells embedded in a mucinous stroma. The tumor cells are typically low-grade, with minimal atypia and low mitotic activity. The presence of mucin is a defining feature, and it can be identified using special staining techniques.

Clinical Presentation

Patients with MTSCC often present with non-specific symptoms, similar to other renal tumors. These may include hematuria, flank pain, or an abdominal mass. However, many cases are discovered incidentally during imaging studies for unrelated conditions.

Diagnosis

The diagnosis of MTSCC is primarily based on histological examination of the tumor tissue obtained via biopsy or surgical resection. Imaging studies such as CT scan or MRI can help in identifying the tumor's location and extent but are not definitive for diagnosis.

Treatment

The primary treatment for MTSCC is surgical resection, typically via nephrectomy. Given its low-grade nature, MTSCC generally has a good prognosis, and complete surgical removal often results in a favorable outcome. Unlike other renal cell carcinomas, MTSCC rarely metastasizes, and adjuvant therapies are usually not required.

Prognosis

The prognosis for patients with MTSCC is generally excellent, with a high survival rate following surgical treatment. Recurrence and metastasis are uncommon, making long-term outcomes favorable compared to other renal malignancies.

See also

• Renal cell carcinoma
• Nephrectomy
• Histopathology